# Merck Says Efinopegdutide Meets Phase 2b MASH Trial Goal

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/53340
Published: 2026-11-10T21:40:17.000Z
Updated: 2026-11-10T21:40:17.000Z
Section: Business

> The MK-6024-013 trial evaluated once-weekly subcutaneous efinopegdutide at 4 mg, 7 mg and 10 mg in adults with MASH and stage F2 or F3 liver fibrosis.

Merck's efinopegdutide met the primary endpoint in a Phase 2b trial of adults with metabolic dysfunction-associated steatohepatitis (MASH) and stage F2 or F3 liver fibrosis.

Merck announced the result Nov. 9 in the MK-6024-013 trial, which tested once-weekly subcutaneous injections at 4 mg, 7 mg and 10 mg.